US4873088A
(en)
*
|
1983-09-06 |
1989-10-10 |
Liposome Technology, Inc. |
Liposome drug delivery method and composition
|
JPS6058915A
(ja)
*
|
1983-09-12 |
1985-04-05 |
Fujisawa Pharmaceut Co Ltd |
薬物含有脂質小胞体製剤
|
EP0152379A3
(de)
*
|
1984-02-15 |
1986-10-29 |
Ciba-Geigy Ag |
Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
|
FR2562421B1
(fr)
*
|
1984-04-09 |
1989-02-17 |
Sandoz Sa |
Perfectionnements a la therapie par l'interleukine
|
US5283122A
(en)
*
|
1984-04-19 |
1994-02-01 |
University Of Tennessee Research Corporation |
Fused liposome and acid induced method for liposome fusion
|
CA1260393A
(en)
*
|
1984-10-16 |
1989-09-26 |
Lajos Tarcsay |
Liposomes of synthetic lipids
|
US4921706A
(en)
*
|
1984-11-20 |
1990-05-01 |
Massachusetts Institute Of Technology |
Unilamellar lipid vesicles and method for their formation
|
JPS62501631A
(ja)
*
|
1985-01-11 |
1987-07-02 |
ザ・リ−ジェンツ・オブ・ジ・ユニバ−シィティ・オブ・カリフォルニア |
リポソ−ムの保持法
|
US4740375A
(en)
*
|
1985-02-25 |
1988-04-26 |
Technology Unlimited, Inc. |
Gelcores
|
US4736051A
(en)
*
|
1985-03-20 |
1988-04-05 |
Kao Corporation |
Process for the preparation of an alkali metal salt of a diester phosphoric acid
|
US5622713A
(en)
*
|
1985-09-17 |
1997-04-22 |
The Regents Of The University Of California |
Method of detoxifying animal suffering from overdose
|
IE58981B1
(en)
*
|
1985-10-15 |
1993-12-15 |
Vestar Inc |
Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
|
MY101125A
(en)
*
|
1985-12-23 |
1991-07-31 |
Kao Corp |
Gel-like emulsion and o/w emulsions obtained from gel-like emulsion
|
US4923854A
(en)
*
|
1986-01-22 |
1990-05-08 |
The Liposome Company, Inc. |
Solubilization of hydrophobic materials using lysophospholipid
|
US4888288A
(en)
*
|
1986-01-30 |
1989-12-19 |
Becton Dickinson And Company |
Vesicles resistant to enzyme lysis and use thereof in an enzyme assay
|
DE3776763D1
(no)
*
|
1986-06-16 |
1992-03-26 |
The Liposome Co.,Inc., Princeton, N.J., Us |
|
US5204112A
(en)
*
|
1986-06-16 |
1993-04-20 |
The Liposome Company, Inc. |
Induction of asymmetry in vesicles
|
US5252263A
(en)
*
|
1986-06-16 |
1993-10-12 |
The Liposome Company, Inc. |
Induction of asymmetry in vesicles
|
JPS63182029A
(ja)
*
|
1987-01-22 |
1988-07-27 |
Agency Of Ind Science & Technol |
リポソ−ム
|
US5154930A
(en)
*
|
1987-03-05 |
1992-10-13 |
The Liposome Company, Inc. |
Pharmacological agent-lipid solution preparation
|
MX9203808A
(es)
*
|
1987-03-05 |
1992-07-01 |
Liposome Co Inc |
Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
|
US4963297A
(en)
*
|
1987-12-22 |
1990-10-16 |
The Liposome Company, Inc. |
Spontaneous vesticulation of multilamellar liposomes
|
CA1338702C
(en)
*
|
1987-03-05 |
1996-11-12 |
Lawrence D. Mayer |
High drug:lipid formulations of liposomal- antineoplastic agents
|
CA1323306C
(en)
*
|
1987-03-05 |
1993-10-19 |
Mircea C. Popescu |
Pharmacological agent-lipid solution preparation
|
FR2616328B1
(fr)
*
|
1987-06-12 |
1990-03-02 |
Moet Hennessy Rech |
Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un extrait de murier, ou au moins une flavone, en particulier une kuwanone et composition pharmaceutique, notamment dermatologique, a activite depigmentante, ou anti-inflammatoire, ou cosmetique, l'incorporant
|
AU618972B2
(en)
*
|
1987-10-06 |
1992-01-16 |
Houston Biotechnology Incorporated |
Phosphatidyl treatment of viral disease
|
US4946683A
(en)
*
|
1987-11-18 |
1990-08-07 |
Vestar, Inc. |
Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
|
CA1330199C
(en)
*
|
1987-12-22 |
1994-06-14 |
Thomas D. Madden |
Spontaneous vesiculation of multilamellar liposomes
|
US5269979A
(en)
*
|
1988-06-08 |
1993-12-14 |
Fountain Pharmaceuticals, Inc. |
Method for making solvent dilution microcarriers
|
US5133965A
(en)
*
|
1988-06-08 |
1992-07-28 |
Fountain Pharmaceuticals, Inc. |
Dressing material having adsorbed thereon a solvent dilution microcarrier precursor solution
|
FR2638639A1
(fr)
*
|
1988-11-08 |
1990-05-11 |
Parincos Parfumerie Cosmet Int |
Composition et procede d'obtention de liposomes oligolamellaires en vue d'une application en cosmetologie et dermatologie topique
|
US5153000A
(en)
*
|
1988-11-22 |
1992-10-06 |
Kao Corporation |
Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
|
US5139803A
(en)
*
|
1989-02-09 |
1992-08-18 |
Nabisco, Inc. |
Method and liposome composition for the stabilization of oxidizable substances
|
US5015483A
(en)
*
|
1989-02-09 |
1991-05-14 |
Nabisco Brands, Inc. |
Liposome composition for the stabilization of oxidizable substances
|
US4994440A
(en)
*
|
1989-02-13 |
1991-02-19 |
Creaven Patrick J |
Method for the treatment of renal cell carcinoma
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
IL94103A0
(en)
*
|
1989-04-25 |
1991-01-31 |
Nattermann A & Cie |
Water-containing formulations with phospholipids,their preparation and application
|
DE3919982A1
(de)
*
|
1989-06-19 |
1990-12-20 |
Liedtke Pharmed Gmbh |
Orale lipidarzneiform
|
US5290563A
(en)
*
|
1989-07-27 |
1994-03-01 |
Laboratoire Des Stallergenes |
Method for combining a mixture of heterogeneous substances with liposomes
|
GB8918879D0
(en)
*
|
1989-08-18 |
1989-09-27 |
Danbiosyst Uk |
Pharmaceutical compositions
|
DE4005711C1
(no)
*
|
1990-02-23 |
1991-06-13 |
A. Nattermann & Cie Gmbh, 5000 Koeln, De |
|
DE4013632A1
(de)
*
|
1990-04-27 |
1991-10-31 |
Max Planck Gesellschaft |
Liposomen mit positiver ueberschussladung
|
US5165994A
(en)
*
|
1990-06-05 |
1992-11-24 |
University Of Delaware |
Spontaneous equilbrium surfactant vesicles
|
DE4018767A1
(de)
*
|
1990-06-12 |
1991-12-19 |
Braun Melsungen Ag |
Wirkstofffreie liposomen zur behandlung von atherosklerose
|
EP0467838A3
(en)
*
|
1990-07-17 |
1992-09-02 |
Ciba-Geigy Ag |
Process for preparing an injectable liposome dispersion
|
CA2046830C
(en)
|
1990-07-19 |
1999-12-14 |
Patrick P. Deluca |
Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
|
FR2674128A1
(fr)
*
|
1991-03-19 |
1992-09-25 |
Patrinove |
"vecteurs de structure capsulaire" et leurs applications dans le transport de substances ou principes actifs.
|
US6764693B1
(en)
|
1992-12-11 |
2004-07-20 |
Amaox, Ltd. |
Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
|
US5720973A
(en)
*
|
1993-02-18 |
1998-02-24 |
Knoll Aktiengesellschaft |
Preparation of colloidal aqueous solutions of active substances of low solubility and a lipid therefor
|
GB9320668D0
(en)
*
|
1993-10-07 |
1993-11-24 |
Secr Defence |
Liposomes containing particulare materials
|
US5840328A
(en)
*
|
1994-01-11 |
1998-11-24 |
The Liposome Company, Inc. |
Treatment using arachidonic acid metabolite and particulate formulations
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
IT1270678B
(it)
*
|
1994-10-20 |
1997-05-07 |
Bayer Ag |
Liposomi al chetoprofen
|
US6093697A
(en)
*
|
1994-11-07 |
2000-07-25 |
The University Of Virginia Patent Foundation |
Synthetic insulin mimetic substances
|
US20020048596A1
(en)
*
|
1994-12-30 |
2002-04-25 |
Gregor Cevc |
Preparation for the transport of an active substance across barriers
|
US20040208922A1
(en)
*
|
1995-06-07 |
2004-10-21 |
The Regents Of The University Of California |
Method for loading lipid like vesicles with drugs or other chemicals
|
US7517858B1
(en)
*
|
1995-06-07 |
2009-04-14 |
The Regents Of The University Of California |
Prodrugs of pharmaceuticals with improved bioavailability
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6071535A
(en)
*
|
1996-01-31 |
2000-06-06 |
Collaborative Laboratories, Inc. |
Lipid vesicles formed with alkylammonium fatty acid salts
|
US5874105A
(en)
*
|
1996-01-31 |
1999-02-23 |
Collaborative Laboratories, Inc. |
Lipid vesicles formed with alkylammonium fatty acid salts
|
US6183774B1
(en)
|
1996-01-31 |
2001-02-06 |
Collaborative Laboratories, Inc. |
Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
|
US6723531B2
(en)
|
1996-04-05 |
2004-04-20 |
The Salk Institute For Biological Studies |
Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
US5766877A
(en)
*
|
1996-05-10 |
1998-06-16 |
Amgen Inc. |
Genes encoding art, an agouti-related transcript
|
ATE302272T1
(de)
|
1996-10-25 |
2005-09-15 |
Human Genome Sciences Inc |
Neutrokin alpha
|
US6593290B1
(en)
|
1996-11-01 |
2003-07-15 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
US6156728A
(en)
|
1996-11-01 |
2000-12-05 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
US5919656A
(en)
|
1996-11-15 |
1999-07-06 |
Amgen Canada Inc. |
Genes encoding telomerase protein 1
|
US7390891B1
(en)
|
1996-11-15 |
2008-06-24 |
Amgen Inc. |
Polynucleotides encoding a telomerase component TP2
|
US5935572A
(en)
*
|
1997-01-10 |
1999-08-10 |
Collaborative Laboratories, Inc. |
Composition containing protease separate from glycosidase for removing nits in treating lice infestation
|
US5827532A
(en)
*
|
1997-01-31 |
1998-10-27 |
The Reagents Of The University Of California |
Method for loading lipsomes with ionizable phosphorylated hydrophobic compounds, pharmaceutical preparations and a method for administering the preparations
|
US6103706A
(en)
*
|
1997-04-29 |
2000-08-15 |
New York Blood Center, Inc. |
Methods for treating viral infections
|
ATE487737T1
(de)
|
1997-05-30 |
2010-11-15 |
Human Genome Sciences Inc |
32 humane sekretierte proteine
|
US6663899B2
(en)
|
1997-06-13 |
2003-12-16 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6113947A
(en)
*
|
1997-06-13 |
2000-09-05 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6300488B1
(en)
|
1997-07-10 |
2001-10-09 |
The Salk Institute For Biological Studies |
Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
AU9221698A
(en)
*
|
1997-09-04 |
1999-03-22 |
Biozone Laboratories, Inc. |
Oral liposomal delivery system
|
US6165997A
(en)
*
|
1997-11-20 |
2000-12-26 |
Statens Serum Institut |
Phospholipids having antimicrobial activity with or without the presence of antimicrobials
|
EP1036164B1
(en)
*
|
1997-11-21 |
2010-06-30 |
Human Genome Sciences, Inc. |
Chemokine alpha-5
|
US5906979A
(en)
*
|
1998-01-27 |
1999-05-25 |
Insmed Pharmaceuticals, Inc. |
Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
|
EP1053009B1
(en)
|
1998-02-04 |
2004-09-22 |
Genentech, Inc. |
Use of heregulin as an epithelial cell growth factor
|
EP2050762A3
(en)
|
1998-03-10 |
2009-07-08 |
Genentech, Inc. |
Human cornichon-like protein and nucleic acids encoding it
|
AU758353B2
(en)
|
1998-03-17 |
2003-03-20 |
Genentech Inc. |
Polypeptides homologous to VEGF and BMP1
|
US6949528B1
(en)
*
|
1998-03-18 |
2005-09-27 |
Goddard John G |
Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
|
EP1093457B8
(en)
|
1998-03-19 |
2011-02-02 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
US6333318B1
(en)
*
|
1998-05-14 |
2001-12-25 |
The Salk Institute For Biological Studies |
Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
US5973119A
(en)
*
|
1998-06-05 |
1999-10-26 |
Amgen Inc. |
Cyclin E genes and proteins
|
US6344541B1
(en)
|
1998-09-25 |
2002-02-05 |
Amgen Inc. |
DKR polypeptides
|
AUPP785098A0
(en)
|
1998-12-21 |
1999-01-21 |
Victor Chang Cardiac Research Institute, The |
Treatment of heart disease
|
DE69825495T2
(de)
|
1998-12-23 |
2005-07-28 |
Idea Ag |
Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
|
ES2173679T3
(es)
|
1999-01-27 |
2002-10-16 |
Idea Ag |
Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
|
PT1031346E
(pt)
|
1999-01-27 |
2002-09-30 |
Idea Ag |
Vacinacao nao invasiva atraves da pele
|
US6303749B1
(en)
|
1999-01-29 |
2001-10-16 |
Amgen Inc. |
Agouti and agouti-related peptide analogs
|
US7708993B2
(en)
|
1999-02-03 |
2010-05-04 |
Amgen Inc. |
Polypeptides involved in immune response
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
US7435796B1
(en)
|
1999-02-03 |
2008-10-14 |
Amgen Inc. |
Antibodies which bind B7RP1
|
DK2332978T3
(da)
|
1999-02-03 |
2014-06-23 |
Amgen Inc |
Nye polypeptider, der er involveret ved et immunrespons
|
AU3501700A
(en)
|
1999-02-26 |
2000-09-14 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
WO2000058479A1
(en)
|
1999-03-26 |
2000-10-05 |
Amgen Inc. |
Beta secretase genes and polypeptides
|
US6635249B1
(en)
|
1999-04-23 |
2003-10-21 |
Cenes Pharmaceuticals, Inc. |
Methods for treating congestive heart failure
|
MXPA02000053A
(es)
|
1999-07-05 |
2003-07-21 |
Idea Ag |
Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7408047B1
(en)
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7057015B1
(en)
|
1999-10-20 |
2006-06-06 |
The Salk Institute For Biological Studies |
Hormone receptor functional dimers and methods of their use
|
US6372722B1
(en)
|
2000-01-19 |
2002-04-16 |
Genteric, Inc. |
Method for nucleic acid transfection of cells
|
US20030103978A1
(en)
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
US7514239B2
(en)
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
AU2001266557A1
(en)
|
2000-04-12 |
2001-10-23 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP2431054A3
(en)
|
2000-06-15 |
2013-03-06 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
EP2275549A1
(en)
|
2000-06-23 |
2011-01-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
CA2648046A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
JP2004519205A
(ja)
|
2000-06-28 |
2004-07-02 |
アムジェン インコーポレイテッド |
胸腺間質リンホポイエチンレセプター分子およびその使用
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
AU2002217969B2
(en)
|
2000-11-28 |
2007-12-20 |
Amgen Canada Inc. |
Polypeptides involved in immune response
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
GB0111628D0
(en)
|
2001-05-11 |
2001-07-04 |
Scancell Ltd |
Binding member
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
WO2003002187A2
(en)
*
|
2001-06-26 |
2003-01-09 |
Photomed Technologies, Inc. |
Multiple wavelength illuminator
|
DE122010000047I1
(de)
|
2001-06-26 |
2011-05-05 |
Amgen Fremont Inc |
Antikörper gegen opgl
|
US7767786B2
(en)
|
2001-08-24 |
2010-08-03 |
Neuren Pharmaceuticals Ltd. |
Neural regeneration peptides and methods for their use in treatment of neural injury or degeneration
|
EP1427830B1
(en)
|
2001-08-29 |
2012-05-09 |
Genentech, Inc. |
Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
DE60230818D1
(de)
|
2001-09-24 |
2009-02-26 |
Imp Innovations Ltd |
Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
|
CA2461998A1
(en)
*
|
2001-09-26 |
2003-04-10 |
Merck & Co., Inc. |
Isolated nucleic acid molecules encoding a bacterial uracil transport protein and a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof
|
EP1930420A1
(en)
|
2001-09-26 |
2008-06-11 |
Merck & Co., Inc. |
Isolated nucleic acid molecules encoding a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof
|
DE10148067A1
(de)
*
|
2001-09-28 |
2003-04-17 |
Max Planck Gesellschaft |
Hitzesterilisierbare Alkylphosphocholin-Liposome
|
DE10148066A1
(de)
*
|
2001-09-28 |
2003-04-24 |
Max Planck Gesellschaft |
Liposome enthaltend (Ether)-Lysolecithine
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US20040106773A1
(en)
*
|
2001-10-12 |
2004-06-03 |
Hao Wang |
Human tuberoinfundibular peptide of 39 residues
|
US20030077282A1
(en)
|
2001-10-12 |
2003-04-24 |
Bigler Michael Eric |
Use of bispecific antibodies to regulate immune responses
|
WO2003060071A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP2329839B1
(en)
|
2002-01-10 |
2015-09-16 |
Imperial Innovations Limited |
Modification of feeding behavior by GLP-1 and PYY
|
US8058233B2
(en)
*
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
US7662924B2
(en)
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
US20030180348A1
(en)
*
|
2002-03-22 |
2003-09-25 |
Levinson R. Saul |
Transcellular drug delivery system
|
MXPA04009681A
(es)
|
2002-04-05 |
2005-01-11 |
Amgen Inc |
Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.
|
WO2003099320A1
(en)
|
2002-05-24 |
2003-12-04 |
Zensun (Shanghai) Sci-Tech.Ltd |
Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
CN100471871C
(zh)
|
2002-09-06 |
2009-03-25 |
安姆根有限公司 |
治疗性人抗-il-1r1单克隆抗体
|
KR100489701B1
(ko)
*
|
2002-10-09 |
2005-05-16 |
주식회사 태평양 |
고농도의 트리터페노이드를 함유하는 미소화 리포좀 및 그제조방법
|
US20040105881A1
(en)
*
|
2002-10-11 |
2004-06-03 |
Gregor Cevc |
Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
|
US7335743B2
(en)
|
2002-10-16 |
2008-02-26 |
Amgen Inc. |
Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
|
US7285269B2
(en)
|
2002-12-02 |
2007-10-23 |
Amgen Fremont, Inc. |
Antibodies directed to tumor necrosis factor
|
MXPA05007019A
(es)
*
|
2002-12-30 |
2005-08-18 |
Amgen Inc |
Terapia de combinacion con factores co-estimuladores.
|
GB0300571D0
(en)
*
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
CN104001158A
(zh)
|
2003-03-12 |
2014-08-27 |
健泰科生物技术公司 |
Bv8和/或EG-VEGF促进造血的用途
|
WO2004084823A2
(en)
|
2003-03-19 |
2004-10-07 |
Abgenix, Inc. |
Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
|
US7291590B2
(en)
|
2003-06-12 |
2007-11-06 |
Queen's University At Kingston |
Compositions and methods for treating atherosclerosis
|
KR20120098932A
(ko)
|
2003-06-27 |
2012-09-05 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
|
PT1648998E
(pt)
|
2003-07-18 |
2014-11-04 |
Amgen Inc |
Agentes de ligação específica ao factor de crescimento do hepatócito
|
WO2005049792A2
(en)
|
2003-09-12 |
2005-06-02 |
Tercica, Inc. |
Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency
|
WO2005044188A2
(en)
|
2003-10-27 |
2005-05-19 |
Amgen Inc. |
Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
|
JP2007530015A
(ja)
*
|
2004-01-05 |
2007-11-01 |
バイオテック・スタジオ・リミテッド・ライアビリティ・カンパニー |
生物治療学的、診断および研究試薬
|
JP4896745B2
(ja)
|
2004-02-02 |
2012-03-14 |
アンブレツクス・インコーポレイテツド |
修飾されたヒトインターフェロンポリペプチドおよびこれらの使用
|
WO2006069220A2
(en)
|
2004-12-22 |
2006-06-29 |
Ambrx, Inc. |
Modified human growth hormone
|
WO2005092926A2
(en)
|
2004-03-19 |
2005-10-06 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through v gene manipulation
|
US7807176B2
(en)
|
2004-03-19 |
2010-10-05 |
Genomidea, Inc. |
Polypeptide promoting vascular endothelial cell growth
|
EP1740208A2
(en)
*
|
2004-03-23 |
2007-01-10 |
Amgen, Inc |
Monoclonal antibodies specific for human ox40l (cd134l)
|
US20050267029A1
(en)
*
|
2004-04-02 |
2005-12-01 |
Ancsin John B |
Compounds which modulate amyloidogenesis and methods for their identification and use
|
GB0410627D0
(en)
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
EP1598428A1
(en)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Methods and kits to detect Hereditary angioedema type III
|
JP2008503217A
(ja)
|
2004-06-18 |
2008-02-07 |
アンブレツクス・インコーポレイテツド |
新規抗原結合ポリペプチド及びそれらの使用
|
DE602005026811D1
(de)
|
2004-06-22 |
2011-04-21 |
Univ Illinois |
Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
KR20070039593A
(ko)
|
2004-07-21 |
2007-04-12 |
암브룩스, 인코포레이티드 |
비천연적으로 코딩된 아미노산을 이용한 생합성 폴리펩티드
|
AU2005267722B2
(en)
|
2004-08-04 |
2009-10-08 |
Amgen Inc. |
Antibodies to Dkk-1
|
CA2577442A1
(en)
|
2004-08-17 |
2006-03-02 |
The Johns Hopkins University |
Pde5 inhibitor compositions and methods for treating cardiac indications
|
EP1799252A4
(en)
|
2004-10-06 |
2009-01-21 |
Agri Biotech Pty Ltd |
ANTIBODY PRODUCTION PROCESS
|
WO2006050926A2
(en)
*
|
2004-11-12 |
2006-05-18 |
Idea Ag |
Extended surface aggregates in the treatment of skin conditions
|
ATE492563T1
(de)
|
2004-11-17 |
2011-01-15 |
Amgen Inc |
Vollständige humane monoklonale antikörper gegen il-13
|
WO2006068975A2
(en)
|
2004-12-20 |
2006-06-29 |
Abgenix, Inc. |
Binding proteins specific for human matriptase
|
ES2371083T3
(es)
|
2004-12-21 |
2011-12-27 |
Medimmune Limited |
Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
|
MX2007007587A
(es)
|
2004-12-22 |
2007-12-11 |
Ambrx Inc |
Formulaciones de la hormona del crecimiento humano que comprenden un aminoacido codificado de manera no natural.
|
KR20070100299A
(ko)
|
2004-12-22 |
2007-10-10 |
암브룩스, 인코포레이티드 |
재조합 인간 성장 호르몬의 발현 및 정제 방법
|
WO2006068802A2
(en)
*
|
2004-12-22 |
2006-06-29 |
Ambrx, Inc. |
COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
|
US7638491B2
(en)
|
2004-12-22 |
2009-12-29 |
Ambrx, Inc. |
Therapies using non-natural amino acids and polypeptides
|
US20060154285A1
(en)
*
|
2004-12-29 |
2006-07-13 |
Robishaw Janet D |
Zebrafish heterotrimer G-protein gamma 2 subunit (GNG2)
|
WO2006081139A2
(en)
|
2005-01-26 |
2006-08-03 |
Abgenix, Inc. |
Antibodies against interleukin-1 beta
|
WO2007059082A1
(en)
|
2005-11-10 |
2007-05-24 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
EP1865967A4
(en)
*
|
2005-04-08 |
2011-02-09 |
Chimerix Inc |
COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES
|
EP1868628B1
(en)
*
|
2005-04-08 |
2014-06-11 |
Chimerix, Inc. |
Compounds, compositions and methods for the treatment of poxvirus infections
|
JP2008540571A
(ja)
|
2005-05-12 |
2008-11-20 |
ウィスコンシン・アルムニ・リサーチ・ファウンデーション |
Pin1の遮断は活性化した免疫細胞によるサイトカイン産生を防ぐ
|
WO2006133089A2
(en)
*
|
2005-06-03 |
2006-12-14 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
GB0511986D0
(en)
*
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
WO2006138181A2
(en)
|
2005-06-14 |
2006-12-28 |
Amgen Inc. |
Self-buffering protein formulations
|
KR101502920B1
(ko)
|
2005-06-21 |
2015-03-17 |
조마 (유에스) 엘엘씨 |
IL-1β 결합성 항체 및 그의 단편
|
BRPI0614040B8
(pt)
|
2005-07-18 |
2021-05-25 |
Amgen Inc |
anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo
|
KR20080033463A
(ko)
|
2005-07-27 |
2008-04-16 |
유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. |
단백질 미스폴딩을 보정하는 작은 화합물 및 그의 용도
|
JP4829969B2
(ja)
*
|
2005-08-18 |
2011-12-07 |
アンブルックス,インコーポレイテッド |
tRNA組成物、およびその使用
|
JP5905184B2
(ja)
|
2005-10-13 |
2016-04-20 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッドHuman Genome Sciences, Inc. |
自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
|
DE602006020480D1
(de)
*
|
2005-11-08 |
2011-04-14 |
Ambrx Inc |
Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide
|
TW200736277A
(en)
|
2005-11-14 |
2007-10-01 |
Amgen Inc |
RANKL antibody-PTH/PTHrP chimeric molecules
|
JP2009520949A
(ja)
|
2005-11-16 |
2009-05-28 |
アンブルックス,インコーポレイテッド |
非天然アミノ酸を含んでいる組成物および方法
|
US20070213264A1
(en)
|
2005-12-02 |
2007-09-13 |
Mingdong Zhou |
Neuregulin variants and methods of screening and using thereof
|
WO2008024128A2
(en)
|
2005-12-05 |
2008-02-28 |
Simon Delagrave |
Loop-variant pdz domains as biotherapeutics, diagnostics and research reagents
|
CA2633956C
(en)
|
2005-12-13 |
2016-12-06 |
Olivia Raeber |
Binding proteins specific for insulin-like growth factors and uses thereof
|
CN101448512B
(zh)
*
|
2005-12-14 |
2015-11-25 |
Ambrx公司 |
含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
|
ATE480559T1
(de)
|
2005-12-14 |
2010-09-15 |
Licentia Ltd |
Verwendungen eines neurotrophischen faktors
|
CN103341168B
(zh)
|
2005-12-15 |
2016-11-02 |
阿斯利康(瑞典)有限公司 |
治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合
|
US20080032343A1
(en)
|
2005-12-22 |
2008-02-07 |
Genentech, Inc. |
Recombinant Production of Heparin Binding Proteins
|
EP2918283B1
(en)
|
2005-12-30 |
2018-01-31 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Extended release of neuregulin for improved cardiac function
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
US20090304704A1
(en)
|
2006-05-03 |
2009-12-10 |
Geisinger Clinic |
Methods for diagnosing and predicting non-alcoholic steatohepatitis (nash)
|
PL2548578T3
(pl)
|
2006-05-17 |
2014-12-31 |
The Ludwig Institute For Cancer Res |
Kierowanie regulacją transporterów kwasów tłuszczowych przez VEGF-B, w celu modulowania ludzkich chorób
|
US8124743B2
(en)
|
2006-06-01 |
2012-02-28 |
President And Fellows Of Harvard College |
Purification of a bivalently active antibody using a non-chromatographic method
|
GB0611405D0
(en)
|
2006-06-09 |
2006-07-19 |
Univ Belfast |
FKBP-L: A novel inhibitor of angiogenesis
|
US20100105610A1
(en)
|
2006-07-28 |
2010-04-29 |
Children's Memorial Hospital |
Methods of Inhibiting Tumor Cell Aggressiveness Using the Microenvironment of Human Embryonic Stem Cells
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
EP2054437A2
(en)
|
2006-08-07 |
2009-05-06 |
Teva Biopharmaceuticals USA, Inc. |
Albumin-insulin fusion proteins
|
AU2007292892B9
(en)
*
|
2006-09-08 |
2013-02-28 |
Ambrx, Inc. |
Hybrid suppressor tRNA for vertebrate cells
|
AU2007292903B2
(en)
|
2006-09-08 |
2012-03-29 |
Ambrx, Inc. |
Modified human plasma polypeptide or Fc scaffolds and their uses
|
CN101511856B
(zh)
*
|
2006-09-08 |
2016-01-20 |
Ambrx公司 |
脊椎动物细胞中抑制因子trna的转录
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
CA2672049C
(en)
|
2006-12-08 |
2016-05-10 |
Lexicon Pharmaceuticals, Inc. |
Monoclonal antibodies against angptl3
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
WO2008077145A2
(en)
|
2006-12-20 |
2008-06-26 |
Xoma Technology Ltd. |
Treatment of il-1-beta related diseases
|
WO2008097926A2
(en)
*
|
2007-02-02 |
2008-08-14 |
Yale University |
Transient transfection with rna
|
US10155038B2
(en)
|
2007-02-02 |
2018-12-18 |
Yale University |
Cells prepared by transient transfection and methods of use thereof
|
US9249423B2
(en)
*
|
2007-02-02 |
2016-02-02 |
Yale University |
Method of de-differentiating and re-differentiating somatic cells using RNA
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
TW201718635A
(zh)
|
2007-03-06 |
2017-06-01 |
安美基公司 |
變異之活動素受體多肽及其用途
|
CA2682147C
(en)
*
|
2007-03-30 |
2017-08-08 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
NZ580686A
(en)
*
|
2007-05-02 |
2012-11-30 |
Ambrx Inc |
Modified interferon beta polypeptides and their uses
|
WO2008140026A1
(ja)
|
2007-05-11 |
2008-11-20 |
Bizen Chemical Co., Ltd. |
新規のロイコトリエン受容体アンタゴニスト
|
WO2009002193A1
(en)
|
2007-06-27 |
2008-12-31 |
Auckland Uniservices Limited |
Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
|
TWI595005B
(zh)
|
2007-08-21 |
2017-08-11 |
安健股份有限公司 |
人類c-fms抗原結合蛋白質
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
EP2615113A3
(en)
|
2007-08-23 |
2013-11-13 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
US20090156488A1
(en)
|
2007-09-12 |
2009-06-18 |
Zensun (Shanghai) Science & Technology Limited |
Use of neuregulin for organ preservation
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
EP2040075A1
(en)
|
2007-09-24 |
2009-03-25 |
Julius-Maximilians-Universität Würzburg |
Compounds and markers for surface-enhanced raman scattering
|
CN101970485B
(zh)
|
2007-09-26 |
2014-05-14 |
U3制药有限公司 |
肝素结合表皮生长因子样生长因子抗原结合蛋白
|
CN101918026B
(zh)
*
|
2007-11-20 |
2016-03-02 |
Ambrx公司 |
经修饰胰岛素多肽和其用途
|
AU2008343085B2
(en)
|
2007-12-20 |
2015-03-12 |
Xoma (Us) Llc |
Methods for the treatment of gout
|
CN101977610B
(zh)
*
|
2008-01-25 |
2012-05-16 |
奇默里克斯公司 |
治疗病毒感染的方法
|
CN101939443B
(zh)
|
2008-02-08 |
2014-01-29 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
FI20080326A0
(fi)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotroofinen tekijä MANF ja sen käytöt
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
AU2009266098B2
(en)
|
2008-06-09 |
2015-01-22 |
Ludwig-Maximilians-Universitat Munchen |
New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
|
WO2009158432A2
(en)
|
2008-06-27 |
2009-12-30 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
ES2654387T3
(es)
|
2008-07-23 |
2018-02-13 |
Ambrx, Inc. |
Polipéptidos G-CSF bovinos modificados y sus usos
|
JP5924937B2
(ja)
|
2008-07-25 |
2016-05-25 |
エックス−ボディ インコーポレイテッド |
タンパク質スクリーニング法
|
AU2009291747B2
(en)
|
2008-09-10 |
2016-05-26 |
Genentech, Inc. |
Methods for inhibiting ocular angiogenesis
|
EP2344536A1
(en)
|
2008-09-19 |
2011-07-20 |
MedImmune, LLC |
Antibodies directed to dll4 and uses thereof
|
MX343802B
(es)
*
|
2008-09-26 |
2016-11-23 |
Ambrx Inc |
Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
|
PT2342223T
(pt)
|
2008-09-26 |
2017-07-07 |
Lilly Co Eli |
Polipéptidos de eritropoetina animal modificados e suas utilizações
|
WO2010034837A1
(en)
*
|
2008-09-26 |
2010-04-01 |
Phares Pharmaceutical Research N.V. |
Method of solubilising biologically active compounds
|
SG195542A1
(en)
|
2008-10-10 |
2013-12-30 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
WO2010062383A2
(en)
|
2008-11-26 |
2010-06-03 |
Amgen Inc. |
Stabilized receptor polypeptides and uses thereof
|
EP2382235B1
(en)
|
2008-12-19 |
2016-02-24 |
Christiane Hilger |
Novel caviidae allergen and uses thereof
|
US20110312872A1
(en)
|
2008-12-22 |
2011-12-22 |
Universität Regensburg |
Norrin in the treatment of diseases associated with an increased tgf-beta activity
|
CA2748158A1
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
EP2390261A4
(en)
|
2009-01-20 |
2012-11-14 |
Hanall Biopharma Co Ltd |
MODIFIED HUMAN THROMBOPOIETIN POLYPEPTIDE FRAGMENT AND METHOD FOR THE PRODUCTION THEREOF
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
CA2751831A1
(en)
|
2009-02-13 |
2010-08-19 |
Novartis Ag |
Nucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof
|
AU2010246038A1
(en)
|
2009-05-05 |
2011-12-01 |
Amgen Inc. |
FGF21 mutants and uses thereof
|
CN107188950B
(zh)
|
2009-05-05 |
2021-09-28 |
安姆根有限公司 |
Fgf21突变体及其用途
|
EP2260857A1
(en)
|
2009-06-11 |
2010-12-15 |
Alfact Innovation |
Novel applications of HIP/PAP or derivatives thereof
|
IN2012DN00352A
(no)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
MX2011013903A
(es)
|
2009-06-17 |
2012-05-08 |
Amgen Inc |
Polipeptidos quimericos y usos de los mismos.
|
US8614200B2
(en)
|
2009-07-21 |
2013-12-24 |
Chimerix, Inc. |
Compounds, compositions and methods for treating ocular conditions
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
EP2305810A1
(en)
|
2009-10-02 |
2011-04-06 |
Technische Universität München |
miRNAs in the treatment of fibrosis
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
CN102711772A
(zh)
|
2009-10-16 |
2012-10-03 |
奥克兰联合服务有限公司 |
Artemin拮抗剂的抗肿瘤用途
|
WO2011056650A2
(en)
|
2009-10-27 |
2011-05-12 |
Michael Zasloff |
Methods and compositions for treating and preventing viral infections
|
SG10201406801XA
(en)
|
2009-11-02 |
2014-11-27 |
Univ Washington |
Therapeutic nuclease compositions and methods
|
CA2780763A1
(en)
|
2009-11-13 |
2011-05-19 |
Puget Sound Blood Center |
Factor viii b cell epitope variants having reduced immunogenicity
|
LT3279215T
(lt)
|
2009-11-24 |
2020-04-10 |
Medimmune Limited |
Tiksliniai surišantys agentai prieš b7-h1
|
WO2011066260A2
(en)
|
2009-11-25 |
2011-06-03 |
Michael Zasloff |
Formulations comprising aminosterols
|
US8491927B2
(en)
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
CA2784800A1
(en)
|
2009-12-21 |
2011-07-21 |
Ambrx, Inc. |
Modified porcine somatotropin polypeptides and their uses
|
EA201290541A1
(ru)
|
2009-12-21 |
2013-05-30 |
Амбркс, Инк. |
Модифицированные бычьи соматотропиновые полипептиды и их применение
|
US20130053438A1
(en)
|
2010-01-19 |
2013-02-28 |
Universitat Innsbruck |
Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
|
JP6046493B2
(ja)
|
2010-01-27 |
2016-12-14 |
チルドレンズ メディカル センター コーポレーション |
プロミニン−1の血管新生促進フラグメントおよびその使用
|
WO2011099007A1
(en)
|
2010-02-10 |
2011-08-18 |
Nayacure Therapeutics Ltd. |
Pharmaceutical compositions and methods for the treatment and prevention of cancer
|
AU2011216243B2
(en)
|
2010-02-12 |
2015-07-09 |
Chimerix, Inc. |
Nucleoside phosphonate salts
|
EP3670534A3
(en)
|
2010-04-15 |
2020-09-09 |
Amgen Inc. |
Human fgf receptor and beta-klotho binding proteins
|
WO2011131626A1
(en)
|
2010-04-19 |
2011-10-27 |
Medizinische Universität Innsbruck |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
EP2563367A4
(en)
|
2010-04-26 |
2013-12-04 |
Chimerix Inc |
METHODS OF TREATING RETROVIRAL INFECTIONS AND ASSOCIATED DOSAGE REGIMES
|
US9320756B2
(en)
|
2010-05-07 |
2016-04-26 |
Centre National De La Recherche Scientifique |
UCP1 (thermogenin)—inducing agents for use in the treatment of a disorder of the energy homeostasis
|
WO2011146938A1
(en)
|
2010-05-21 |
2011-11-24 |
NanoOncology, Inc. |
Reagents and methods for treating cancer
|
RU2615684C2
(ru)
|
2010-06-14 |
2017-04-06 |
Ликера Биомед Са |
Специфическое антитело к s100a4 или его фрагмент (варианты), способ их получения (варианты), фармацевтическая композиция, их содержащая, гибридомная клеточная линия (варианты), конъюгат, композиция, способ предупреждения и/или лечения рака, метастазирования, ангиогенеза и воспалительных заболеваний, способ и набор для диагностики рака или заболевания, ассоциированного с воспалением, (варианты), способ детекции s100a4, способ создания индивидуальной терапии
|
JP5709985B2
(ja)
|
2010-06-18 |
2015-04-30 |
シーバーサイエンス ゲーエムベーハー |
生体バリアを安定化させる活性剤としてのペプチド
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
MA34521B1
(fr)
|
2010-08-17 |
2013-09-02 |
Ambrx Inc |
Polypeptides de relaxine modifiés et leurs utilisations
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
EP2632951B1
(en)
|
2010-10-27 |
2017-08-02 |
Amgen Inc. |
Dkk1 antibodies and methods of use
|
AU2011323508B2
(en)
|
2010-11-01 |
2017-04-27 |
Peptimed, Inc. |
Compositions of a peptide targeting system for treating cancer
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
SG189982A1
(en)
|
2010-11-24 |
2013-06-28 |
Lexicon Pharmaceuticals Inc |
Antibodies to notum pectinacetylesterase
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
EP2665746B1
(en)
|
2011-01-17 |
2020-10-28 |
Lykera Biomed S.A. |
Antibodies against the s100p protein for the treatment and diagnosis of cancer
|
WO2012102679A1
(en)
|
2011-01-24 |
2012-08-02 |
National University Of Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
RS56461B1
(sr)
|
2011-01-27 |
2018-01-31 |
Neuren Pharmaceuticals Ltd |
Tretman bolesti iz spektra autizma upotrebom glicil-l-2-metilprolil-l-glutaminske kiseline
|
EP2681242B1
(en)
|
2011-03-01 |
2018-01-24 |
Amgen Inc. |
Sclerostin and dkk-1 bispecific binding agents
|
MX2013010185A
(es)
|
2011-03-10 |
2014-02-17 |
Genentech Inc |
Tratamiento de alteraciones con funcion de barrera vascular alterada.
|
JP5908972B2
(ja)
|
2011-04-07 |
2016-04-26 |
アムジエン・インコーポレーテツド |
新規な抗原結合タンパク質
|
MX343729B
(es)
|
2011-04-08 |
2016-11-18 |
Amgen Inc |
Factor de diferenciación de crecimiento 15 (gdf-15) y composiciones del mismo para usarse en el tratamiento o mejoramiento de trastornos metabólicos.
|
MX351953B
(es)
|
2011-04-29 |
2017-11-06 |
Univ Washington |
Composiciones de nucleasa terapeuticas y metodos.
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
JP2014513981A
(ja)
|
2011-05-10 |
2014-06-19 |
アムジエン・インコーポレーテツド |
FGFR1とβ−KLOTHOの相互作用を特異的に調節する化合物の同定方法
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
US9133082B2
(en)
|
2011-06-14 |
2015-09-15 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
US20140227265A1
(en)
|
2011-06-17 |
2014-08-14 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using clec-2
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
CA2843369A1
(en)
|
2011-08-16 |
2013-02-21 |
Evotec (Munchen) Gmbh |
Markers for susceptibility to an inhibitor of an src-family kinase
|
EP2744828A4
(en)
|
2011-08-16 |
2014-12-31 |
Univ Emory |
JAML-SPECIFIC BINDING AGENTS, ANTIBODIES AND USES THEREOF
|
CA2845357A1
(en)
|
2011-08-31 |
2013-03-07 |
Amgen Inc. |
Method of treating or ameliorating type 1 diabetes using fgf21
|
EA201790757A1
(ru)
|
2011-09-22 |
2017-07-31 |
Эмджен Инк. |
Связывающие антиген cd27l белки
|
US9458214B2
(en)
|
2011-09-26 |
2016-10-04 |
Novartis Ag |
Dual function fibroblast growth factor 21 proteins
|
US9006400B2
(en)
|
2011-09-26 |
2015-04-14 |
Novartis Ag |
Fibroblast growth factor-21-Fc fusion proteins
|
WO2013053076A1
(en)
|
2011-10-10 |
2013-04-18 |
Zensun (Shanghai)Science & Technology Limited |
Compositions and methods for treating heart failure
|
US8906860B2
(en)
|
2011-10-14 |
2014-12-09 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions inhibiting tumor cell proliferation
|
WO2013056255A1
(en)
|
2011-10-14 |
2013-04-18 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions for inhibiting tumor cell proliferation
|
MX2014005957A
(es)
|
2011-11-16 |
2015-02-04 |
Amgen Inc |
Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico.
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
EP2944628B1
(en)
|
2011-11-30 |
2017-01-04 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
EP2601941A1
(en)
|
2011-12-06 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
|
CN104220460A
(zh)
|
2011-12-08 |
2014-12-17 |
安姆根有限公司 |
激动人lcat抗原结合蛋白和它们在疗法中的用途
|
EP2788500A1
(en)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
SG11201403367YA
(en)
|
2011-12-19 |
2014-07-30 |
Amgen Inc |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
CN104144946A
(zh)
|
2011-12-19 |
2014-11-12 |
爱克索马美国有限责任公司 |
治疗痤疮的方法
|
EP3663314A1
(en)
|
2012-01-09 |
2020-06-10 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
EP2802603A4
(en)
|
2012-01-09 |
2015-11-04 |
Scripps Research Inst |
REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF
|
WO2013113008A1
(en)
|
2012-01-26 |
2013-08-01 |
Amgen Inc. |
Growth differentiation factor 15 (gdf-15) polypeptides
|
EP2626066A1
(en)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
WO2013172954A1
(en)
|
2012-05-17 |
2013-11-21 |
Ra Pharmaceuticals, Inc |
Peptide and peptidomimetic inhibitors
|
JO3623B1
(ar)
|
2012-05-18 |
2020-08-27 |
Amgen Inc |
البروتينات المرتبطة بمولد المستضاد st2
|
EP2666775A1
(en)
|
2012-05-21 |
2013-11-27 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
WO2013177187A2
(en)
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
EP2866821B1
(en)
|
2012-07-02 |
2018-11-14 |
Medizinische Universität Wien |
Complement split product c4d for the treatment of inflammatory conditions
|
EP2687225A1
(en)
|
2012-07-19 |
2014-01-22 |
Alfact Innovation |
HIP/PAP protein and derivatives thereof for use in treating cancer
|
EP2695950A1
(en)
|
2012-08-10 |
2014-02-12 |
Blackfield AG |
Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
|
JP2015526471A
(ja)
|
2012-08-21 |
2015-09-10 |
ジェネシス リサーチ インスティチュート |
アントラサイクリン誘発性心毒性を治療または予防するための組成物および方法
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
CN104813168B
(zh)
|
2012-11-30 |
2017-10-20 |
霍夫曼-拉罗奇有限公司 |
需要pd‑l1抑制剂综合疗法的患者的鉴定
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
US9920121B2
(en)
|
2013-01-25 |
2018-03-20 |
Amgen Inc. |
Antibodies targeting CDH19 for melanoma
|
CA2899889A1
(en)
|
2013-02-01 |
2014-08-07 |
Santa Maria Biotherapeutics, Inc. |
Administration of an anti-activin-a compound to a subject
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
CA2904337A1
(en)
|
2013-03-14 |
2014-10-02 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
WO2014144553A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
|
US9708375B2
(en)
|
2013-03-15 |
2017-07-18 |
Amgen Inc. |
Inhibitory polypeptides specific to WNT inhibitors
|
WO2014151834A2
(en)
|
2013-03-15 |
2014-09-25 |
Amgen Inc. |
Methods and compositions relating to anti-ccr7 antigen binding proteins
|
EP2970449B1
(en)
|
2013-03-15 |
2019-09-25 |
Amgen Research (Munich) GmbH |
Single chain binding molecules comprising n-terminal abp
|
AU2014236728B2
(en)
|
2013-03-15 |
2018-09-13 |
Amgen Inc. |
Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides
|
AU2014228924B2
(en)
|
2013-03-15 |
2019-04-18 |
Amgen Inc. |
Human PAC1 antibodies
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
EP2984108B1
(en)
|
2013-04-09 |
2017-05-31 |
Lykera Biomed, S.A. |
Anti-s100a7 antibodies for the treatment and diagnosis of cancer
|
EP2801370A1
(en)
|
2013-05-07 |
2014-11-12 |
Fundació Privada Institut d'Investigació Oncològica de Vall Hebron |
Methods and compositions for the treatment of cancer
|
US10501803B2
(en)
|
2013-05-21 |
2019-12-10 |
Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. |
Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
|
KR102578135B1
(ko)
|
2013-05-22 |
2023-09-13 |
젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드 |
심부전을 치료하기 위한 뉴레귤린의 연장 방출
|
WO2014191630A2
(en)
|
2013-05-28 |
2014-12-04 |
Helsingin Yliopisto |
Non-human animal model encoding a non-functional manf gene
|
HUE040548T2
(hu)
|
2013-05-30 |
2019-03-28 |
Kiniksa Pharmaceuticals Ltd |
Onkosztatin-M-receptor antigénjét kötõ fehérjék
|
EP2810648A1
(en)
|
2013-06-04 |
2014-12-10 |
Daniel Rauh |
Targeting domain-domain interaction for the identification of kinase modulators
|
EP2835135A3
(en)
|
2013-06-19 |
2015-06-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
Means and methods for treating pseudomonas infection
|
EP3013422A1
(en)
|
2013-06-28 |
2016-05-04 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
WO2014207213A1
(en)
|
2013-06-28 |
2014-12-31 |
Medizinische Universität Innsbruck |
Novel inhibitors of protein kinase c epsilon signaling
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
AU2014290361B2
(en)
|
2013-07-18 |
2019-04-18 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementarity determining regions
|
HUE050630T2
(hu)
|
2013-07-31 |
2020-12-28 |
Amgen Inc |
Növekedési differenciációs faktor 15 (GDF15) konstrukciók
|
WO2015022326A1
(en)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides as active agents for treating primary graft dysfunction
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
EP3041863A4
(en)
|
2013-09-05 |
2017-08-16 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
AR097648A1
(es)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
|
US10286078B2
(en)
|
2013-09-13 |
2019-05-14 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
CA2924370C
(en)
|
2013-09-16 |
2024-01-23 |
Robert Kralovics |
Mutant calreticulin for the diagnosis of myeloid malignancies
|
US9957506B2
(en)
|
2013-09-25 |
2018-05-01 |
Cornell University |
Compounds for inducing anti-tumor immunity and methods thereof
|
CA2927543C
(en)
|
2013-10-15 |
2021-07-20 |
The California Institute For Biomedical Research |
Peptidic chimeric antigen receptor t cell switches and uses thereof
|
ES2741308T3
(es)
|
2013-10-15 |
2020-02-10 |
Scripps Research Inst |
Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos
|
US20160235810A1
(en)
|
2013-10-18 |
2016-08-18 |
Novartis Ag |
Methods of treating diabetes and related disorders
|
WO2015066557A1
(en)
|
2013-10-31 |
2015-05-07 |
Resolve Therapeutics, Llc |
Therapeutic nuclease molecules with altered glycosylation and methods
|
GB201319374D0
(en)
|
2013-11-01 |
2013-12-18 |
Univ Nottingham |
Glycans as functional cancer targets abd antibodies thereto
|
US10039809B2
(en)
|
2013-12-18 |
2018-08-07 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
CN103965357B
(zh)
|
2013-12-31 |
2016-08-17 |
嘉和生物药业有限公司 |
一种抗人rankl抗体
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
WO2015121457A1
(en)
|
2014-02-13 |
2015-08-20 |
Westphal Sören |
Fgf-8 for use in treating diseases or disorders of energy homeostasis
|
WO2015127134A2
(en)
|
2014-02-20 |
2015-08-27 |
Allergan, Inc. |
Complement component c5 antibodies
|
EP3110845A1
(en)
|
2014-02-27 |
2017-01-04 |
Allergan, Inc. |
Complement factor bb antibodies
|
CA2888068A1
(en)
|
2014-04-15 |
2015-10-15 |
The Hospital For Sick Children |
Cationic antimicrobial peptides
|
EP3143143A1
(en)
|
2014-05-15 |
2017-03-22 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Antagonists of slc38a9 and their use in therapy
|
WO2015179415A1
(en)
|
2014-05-19 |
2015-11-26 |
Novartis Ag |
Methods of treating anorexia
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
KR20170035891A
(ko)
|
2014-06-13 |
2017-03-31 |
산타 마리아 바이오테라퓨틱스, 인코포레이티드 |
제형화된 수용체 폴리펩타이드 및 관련 방법
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
JP6749312B2
(ja)
|
2014-07-31 |
2020-09-02 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH |
最適化された種間特異的二重特異性単鎖抗体コンストラクト
|
US9872908B2
(en)
*
|
2014-08-09 |
2018-01-23 |
Avanti Polar Lipids, Inc. |
Oral composition for delivery of drugs and other substances
|
US20170216403A1
(en)
|
2014-08-12 |
2017-08-03 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
US10166273B2
(en)
|
2014-08-12 |
2019-01-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein
|
WO2016029191A2
(en)
|
2014-08-22 |
2016-02-25 |
Auckland Uniservices Limited |
Channel modulators
|
BR112017003986A2
(pt)
|
2014-08-27 |
2018-02-27 |
Peptimed Inc |
composições e métodos anti-tumor
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
EP3000814A1
(en)
|
2014-09-26 |
2016-03-30 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
LT3412302T
(lt)
|
2014-10-24 |
2021-07-26 |
Bristol-Myers Squibb Company |
Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
|
WO2016069889A1
(en)
|
2014-10-31 |
2016-05-06 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-transferrin fusions and methods
|
WO2016079321A1
(en)
|
2014-11-20 |
2016-05-26 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of setdb2 for use in the therapy of infectious diseases
|
EP3085709B1
(en)
|
2014-12-28 |
2019-08-21 |
Genor Biopharma Co., Ltd |
Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
|
WO2016123142A1
(en)
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
IL13RAα2 BINDING AGENTS AND USE THEREOF IN CANCER TREATMENT
|
JP6912386B2
(ja)
|
2015-01-26 |
2021-08-04 |
ザ ユニバーシティー オブ シカゴ |
癌特異的なIL13Rα2を認識するCAR T細胞
|
WO2016135130A1
(en)
|
2015-02-23 |
2016-09-01 |
Serini Guido |
Non-natural semaphorins 3 and their medical use
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
CR20170510A
(es)
|
2015-04-10 |
2018-02-26 |
Amgen Inc |
Muteínas de interuquina 2 para la expansión de células t regulatorias
|
EP3283113A4
(en)
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
CA2982682A1
(en)
|
2015-04-17 |
2016-10-20 |
Amgen Research (Munich) Gmbh |
Bispecific antibody constructs for cdh3 and cd3
|
WO2016170102A1
(en)
|
2015-04-22 |
2016-10-27 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
US20160361380A1
(en)
|
2015-06-12 |
2016-12-15 |
Nymox Corporation |
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
|
US20190000928A1
(en)
|
2015-06-17 |
2019-01-03 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
WO2017007955A1
(en)
|
2015-07-07 |
2017-01-12 |
The Research Foundation For The State University Of New York |
Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
WO2017059371A1
(en)
|
2015-10-01 |
2017-04-06 |
Amgen Inc. |
Treatment of bile acid disorders
|
WO2017079215A1
(en)
|
2015-11-03 |
2017-05-11 |
Glycomimetics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
AU2016354661B2
(en)
|
2015-11-13 |
2020-12-10 |
Domain Therapeutics |
Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors
|
US20170157215A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
LT3386997T
(lt)
|
2015-12-09 |
2021-12-10 |
Medizinische Universität Wien |
Monomaleimidu funkcionalizuoti platinos junginiai, skirti vėžio terapijai
|
US10294303B2
(en)
|
2015-12-23 |
2019-05-21 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
|
CN109071482A
(zh)
|
2016-01-15 |
2018-12-21 |
汉堡大学 |
携有o-鼠李糖基残基的类黄酮型化合物
|
JOP20170017B1
(ar)
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
DK3411402T3
(da)
|
2016-02-03 |
2022-02-07 |
Amgen Res Munich Gmbh |
Bcma- og cd3-bispecifikke t-celle-engagerende antistofkonstruktioner
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
CN109311979A
(zh)
|
2016-02-03 |
2019-02-05 |
安进研发(慕尼黑)股份有限公司 |
Psma和cd3双特异性t细胞接合抗体构建体
|
US10702518B2
(en)
|
2016-02-15 |
2020-07-07 |
CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH |
TAF1 inhibitors for the therapy of cancer
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
WO2017176916A1
(en)
*
|
2016-04-05 |
2017-10-12 |
The Research Foundation For The State University Of New York |
Phosphoserine containing compositions for immune tolerance induction
|
ES2957548T3
(es)
|
2016-04-15 |
2024-01-22 |
Univ Oxford Innovation Ltd |
Moduladores del receptor de adenosina para el tratamiento de los trastornos del ritmo circadiano
|
CN115073581A
(zh)
|
2016-05-04 |
2022-09-20 |
美国安进公司 |
用于扩增t调节性细胞的白细胞介素-2突变蛋白
|
US10183058B2
(en)
|
2016-06-17 |
2019-01-22 |
Nymox Corporation |
Method of preventing or reducing the progression of prostate cancer
|
MA45554A
(fr)
|
2016-07-01 |
2019-05-08 |
Resolve Therapeutics Llc |
Fusions de binucléase optimisées.
|
WO2018013924A1
(en)
|
2016-07-15 |
2018-01-18 |
Massachusetts Institute Of Technology |
Synthetic nanoparticles for delivery of immunomodulatory compounds
|
EP3269734A1
(en)
|
2016-07-15 |
2018-01-17 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Methods and compositions for the treatment of cancer
|
US10172910B2
(en)
|
2016-07-28 |
2019-01-08 |
Nymox Corporation |
Method of preventing or reducing the incidence of acute urinary retention
|
EP3493848B1
(en)
|
2016-08-02 |
2021-09-29 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Heterocyclic diamidines
|
JP2019527710A
(ja)
|
2016-08-08 |
2019-10-03 |
アムジエン・インコーポレーテツド |
抗スクレロスチン抗体を用いた結合組織付着の改善方法
|
US10532081B2
(en)
|
2016-09-07 |
2020-01-14 |
Nymox Corporation |
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
|
CN110267982B
(zh)
|
2016-10-19 |
2024-02-23 |
斯克利普斯研究所 |
具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
|
AU2017359288A1
(en)
|
2016-11-14 |
2019-05-30 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of a BRD4 inhibitor and an antifolate for the therapy of cancer
|
US11091490B2
(en)
|
2016-11-30 |
2021-08-17 |
Medizinische Universität Innsbruck |
3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors
|
WO2018128454A1
(ko)
|
2017-01-06 |
2018-07-12 |
에이비엘바이오 주식회사 |
항 α-SYN 항체 및 그 용도
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
SG11201907209QA
(en)
|
2017-02-08 |
2019-09-27 |
Bristol Myers Squibb Co |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
US10335453B2
(en)
|
2017-03-01 |
2019-07-02 |
Nymox Corporation |
Compositions and methods for improving sexual function
|
WO2018160791A1
(en)
|
2017-03-03 |
2018-09-07 |
Massachusetts Institute Of Technology |
Antimicrobial constructs and uses thereof
|
CN110913904A
(zh)
|
2017-05-05 |
2020-03-24 |
美国安进公司 |
用于改善的储存和施用的包含双特异性抗体构建体的药物组合物
|
CA3062749A1
(en)
|
2017-05-12 |
2018-11-15 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. |
Compounds for use in the treatment or prevention of melanoma
|
WO2018206820A1
(en)
|
2017-05-12 |
2018-11-15 |
Mavalon Therapeutics Limited |
Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
MX2019013919A
(es)
|
2017-06-20 |
2020-01-21 |
Amgen Inc |
Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
|
CA3069438A1
(en)
|
2017-07-11 |
2019-01-17 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
CN111372599A
(zh)
|
2017-07-19 |
2020-07-03 |
奥克兰联合服务有限公司 |
细胞因子调节
|
EP3665202A1
(en)
|
2017-08-09 |
2020-06-17 |
Massachusetts Institute Of Technology |
Albumin binding peptide conjugates and methods thereof
|
WO2019036605A2
(en)
|
2017-08-17 |
2019-02-21 |
Massachusetts Institute Of Technology |
MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
|
MX2020002070A
(es)
|
2017-08-22 |
2020-03-24 |
Sanabio Llc |
Receptores solubles de interferon y usos de los mismos.
|
US20200230221A1
(en)
|
2017-09-19 |
2020-07-23 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
EP3692061A1
(en)
|
2017-10-04 |
2020-08-12 |
Amgen Inc. |
Transthyretin immunoglobulin fusions
|
EP3704132A4
(en)
|
2017-10-30 |
2021-07-28 |
Enterin, Inc. |
NEW SOLID FORMS OF SQUALAMINE AND PROCESSES FOR PRODUCING THEM
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
WO2019110139A1
(en)
|
2017-12-05 |
2019-06-13 |
Eth Zurich |
New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
|
CN111315780A
(zh)
|
2017-12-11 |
2020-06-19 |
安进公司 |
双特异性抗体产品的连续制造工艺
|
US11224648B2
(en)
|
2017-12-19 |
2022-01-18 |
Massachusetts Institute Of Technology |
Antigen-adjuvant coupling reagents and methods of use
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
CN112262155A
(zh)
|
2018-03-14 |
2021-01-22 |
表面肿瘤学公司 |
结合cd39的抗体及其用途
|
CN112512571A
(zh)
|
2018-03-22 |
2021-03-16 |
表面肿瘤学公司 |
抗il-27抗体及其用途
|
WO2019191534A1
(en)
|
2018-03-30 |
2019-10-03 |
Amgen Inc. |
C-terminal antibody variants
|
US20210163406A1
(en)
|
2018-04-06 |
2021-06-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
|
CA3096146A1
(en)
|
2018-04-06 |
2019-10-10 |
Zilentin AG |
Bumetanide derivatives for the therapy of hyperhidrosis
|
KR20200140878A
(ko)
|
2018-04-09 |
2020-12-16 |
암젠 인크 |
성장 분화 인자 15 융합 단백질
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
WO2019204743A1
(en)
|
2018-04-19 |
2019-10-24 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
TW202003580A
(zh)
|
2018-05-21 |
2020-01-16 |
美商坎伯斯治療有限責任公司 |
用於增強nk細胞對標靶細胞之殺死之組合物及方法
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
US20220275043A1
(en)
|
2018-07-17 |
2022-09-01 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
WO2020033923A1
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
EP3833442A2
(en)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antibodies that bind cd277 and uses thereof
|
MX2021002301A
(es)
|
2018-08-28 |
2021-04-28 |
Ambrx Inc |
Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
|
SG11202102427XA
(en)
|
2018-09-11 |
2021-04-29 |
Ambrx Inc |
Interleukin-2 polypeptide conjugates and their uses
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
CA3113618A1
(en)
|
2018-09-28 |
2020-04-02 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
JP2022512636A
(ja)
|
2018-10-11 |
2022-02-07 |
アムジエン・インコーポレーテツド |
二重特異性抗体コンストラクトの下流プロセシング
|
JP2022512746A
(ja)
|
2018-10-19 |
2022-02-07 |
アンブルックス,インコーポレイテッド |
インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用
|
AU2019379576A1
(en)
|
2018-11-13 |
2021-06-03 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
AU2019407650B2
(en)
|
2018-12-17 |
2022-10-27 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
WO2020142740A1
(en)
|
2019-01-04 |
2020-07-09 |
Resolve Therapeutics, Llc |
Treatment of sjogren's disease with nuclease fusion proteins
|
WO2020154032A1
(en)
|
2019-01-23 |
2020-07-30 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
GB201901305D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Specific binding molecules
|
KR20210136014A
(ko)
|
2019-02-12 |
2021-11-16 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도
|
KR20220012839A
(ko)
|
2019-03-19 |
2022-02-04 |
펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론 |
Omomyc와 pd-1 또는 ctla-4에 결합하는 항체를 이용한 암 치료용 조합 요법
|
US20200345853A1
(en)
|
2019-03-20 |
2020-11-05 |
Massachusetts Institute Of Technology |
Uses of amphiphiles in immune cell therapy and compositions therefor
|
TW202045711A
(zh)
|
2019-06-13 |
2020-12-16 |
美商安進公司 |
生物製品製造中基於生物量之自動灌注控制
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
US20220324924A1
(en)
|
2019-07-08 |
2022-10-13 |
Amgen Inc. |
Multispecific transthyretin immunoglobulin fusions
|
JP2022542890A
(ja)
|
2019-07-26 |
2022-10-07 |
アムジエン・インコーポレーテツド |
抗il13抗原結合タンパク質
|
GB201910899D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Binding members
|
GB201910900D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
|
EP4013788A1
(en)
|
2019-08-12 |
2022-06-22 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
|
US20220289807A1
(en)
|
2019-08-13 |
2022-09-15 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
GB201912657D0
(en)
|
2019-09-03 |
2019-10-16 |
Scancell Ltd |
Binding members
|
GB201912882D0
(en)
|
2019-09-06 |
2019-10-23 |
Scancell Ltd |
Ssea-4 binding members
|
MX2022003005A
(es)
|
2019-09-16 |
2022-04-07 |
Surface Oncology Inc |
Composiciones y metodos de anticuerpos anti-cd39.
|
AU2020353672A1
(en)
|
2019-09-25 |
2022-03-31 |
Surface Oncology, LLC |
Anti-IL-27 antibodies and uses thereof
|
WO2021064141A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
|
CA3153456A1
(en)
|
2019-10-02 |
2021-04-08 |
Stefanie Fluckiger-Mangual |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
EP4045142A1
(en)
|
2019-10-16 |
2022-08-24 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
AU2020372478A1
(en)
|
2019-10-23 |
2022-06-02 |
Checkmate Pharmaceuticals, Inc. |
Synthetic RIG-I-like receptor agonists
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
JP2022554187A
(ja)
|
2019-10-24 |
2022-12-28 |
ミノトール セラピューティクス インコーポレイテッド |
キメラサイトカイン改変抗体およびその使用方法
|
AU2020381536A1
(en)
|
2019-11-13 |
2022-04-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
IL292919A
(en)
|
2019-11-19 |
2022-07-01 |
Modag Gmbh |
New compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
|
CN114867749A
(zh)
|
2019-12-17 |
2022-08-05 |
安进公司 |
用于疗法中的双重白介素-2/tnf受体激动剂
|
EP4087607A1
(en)
|
2020-01-06 |
2022-11-16 |
Vaccinex, Inc. |
Anti-ccr8 antibodies and uses thereof
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
IL296099A
(en)
|
2020-03-11 |
2022-11-01 |
Ambrx Inc |
Interleukin-2 polypeptide conjugates and methods of using them
|
MX2022011632A
(es)
|
2020-03-19 |
2022-10-13 |
Amgen Inc |
Anticuerpos contra mucina 17 y usos de los mismos.
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
BR112022026045A2
(pt)
|
2020-06-25 |
2023-01-17 |
Tolremo Therapeutics Ag |
Derivados heterocíclicos, composições farmacêutucas e seu uso no tratamento, melhora ou prevenção de doença fibrótica
|
CA3165342A1
(en)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
EP3939578A1
(en)
|
2020-07-13 |
2022-01-19 |
Novaremed Ltd. |
Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
|
WO2022023292A2
(en)
|
2020-07-31 |
2022-02-03 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Corona virus spike protein-targeting antibodies and use thereof
|
AU2021327396A1
(en)
|
2020-08-20 |
2023-03-23 |
Ambrx, Inc. |
Antibody-TLR agonist conjugates, methods and uses thereof
|
BR112023002195A2
(pt)
|
2020-08-26 |
2023-03-14 |
Scancell Ltd |
Ácido nucleico que codifica um polipeptídeo, vetor, peptídeo, e composição de vacina
|
EP3964497A1
(en)
|
2020-09-04 |
2022-03-09 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
|
EP4229081A1
(en)
|
2020-10-15 |
2023-08-23 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
JP2023545588A
(ja)
|
2020-10-16 |
2023-10-30 |
ツェーエムエム-フォルシュングスツェントルム フュア モレクラレ メディツィン ゲーエムベーハー |
ヘテロ環式カリンringユビキチンリガーゼ化合物及びその使用
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
EP4240768A2
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
CA3209052A1
(en)
|
2021-02-19 |
2022-08-25 |
Rafael Cristian CASELLAS |
Single domain antibodies that neutralize sars-cov-2
|
WO2022212899A1
(en)
|
2021-04-03 |
2022-10-06 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|
WO2022214606A1
(en)
|
2021-04-07 |
2022-10-13 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
AU2022264339A1
(en)
|
2021-04-28 |
2023-11-09 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
CN117279947A
(zh)
|
2021-05-06 |
2023-12-22 |
安进研发(慕尼黑)股份有限公司 |
用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
|
WO2022236134A1
(en)
|
2021-05-07 |
2022-11-10 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
WO2022241465A1
(en)
|
2021-05-14 |
2022-11-17 |
Claris Biotherapeutics, Inc. |
Compositions of growth factor for the treatment of eye disease
|
TW202323276A
(zh)
|
2021-09-03 |
2023-06-16 |
瑞士伯恩大學 |
用於治療長qt症候群之組成物及方法
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
CA3233696A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
WO2023203378A1
(en)
|
2022-04-19 |
2023-10-26 |
Garth Cooper |
Treatment of brain copper disorders
|
WO2023203174A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
US20240025987A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
WO2023230128A1
(en)
|
2022-05-25 |
2023-11-30 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
WO2024050526A1
(en)
|
2022-09-02 |
2024-03-07 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating long qt syndrome
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024076995A1
(en)
|
2022-10-03 |
2024-04-11 |
Insigna Inc. |
Compositions for non-surgical prevention of boar taint and aggressive behavior
|